Gut bacteria targeted in fight against advanced prostate cancer
NCT ID NCT06126731
Summary
This early-stage trial is testing whether a combination of common antibiotics can change the gut bacteria (microbiome) to help a prostate cancer drug work better. It is for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to see if the antibiotic combination is safe when taken with the cancer drug enzalutamide and to check for any early signs that it can slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oncolgy Institute of Southern Switzerland (IOSI)
RECRUITINGBellinzona, Switzerland
Contact Email: •••••@•••••
-
The Royal Marsden NHS Foundation Trust
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.